Opinion|Videos|February 10, 2025
Management of Tardive Dyskinesia and Comorbidities
Panelists discuss how managing tardive dyskinesia in patients with comorbid mental health conditions requires a delicate balance between treating TD symptoms while maintaining psychiatric stability, emphasizing the importance of coordinated care between psychiatrists and movement disorder specialists to optimize medication regimens, monitor for potential drug interactions, and address the complex interplay between physical symptoms and psychological well-being.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- How does the burden of comorbid conditions, such as mental health disorders, influence the management and outcomes of patients with TD?
- How does the long-term management of TD align with treatment strategies for other movement disorders, and what challenges or opportunities arise when managing coexisting conditions
Advertisement
Related to this article
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5